Stock A215600 SILLAJEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials SillaJen, Inc.

Equities

A215600

KR7215600008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 17/05/2024 am IST 		5-day change 1st Jan Change
4,655 KRW +1.97% Intraday chart for SillaJen, Inc. +7.63% -22.80%
22/04 OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market CI
27/03 SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 51,31,552 10,33,808 8,66,567 12,43,785 7,16,461 6,19,837
Enterprise Value (EV) 1 50,21,763 9,85,877 8,60,153 11,39,382 6,56,589 5,80,236
P/E ratio -90.5 x -9.09 x -18.1 x -63.9 x -29.1 x -30.4 x
Yield - - - - - -
Capitalization / Revenue 665 x 114 x 519 x 4,890 x 143 x 157 x
EV / Revenue 651 x 109 x 515 x 4,479 x 131 x 147 x
EV / EBITDA -90.1 x -17.9 x -26.1 x -59.2 x -28.2 x -28.5 x
EV / FCF -195 x -26.1 x -35.8 x -224 x -18.1 x -44.1 x
FCF Yield -0.51% -3.83% -2.79% -0.45% -5.53% -2.27%
Price to Book 31.1 x 16.9 x 37.8 x 11.5 x 9.08 x 10.8 x
Nbr of stocks (in thousands) 69,817 71,052 71,617 1,02,792 1,02,792 1,02,792
Reference price 2 73,500 14,550 12,100 12,100 6,970 6,030
Announcement Date 19/03/19 30/03/20 22/03/21 22/03/22 23/03/23 21/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,712 9,069 1,670 254.4 5,013 3,940
EBITDA 1 -55,740 -55,149 -32,933 -19,239 -23,248 -20,326
EBIT 1 -59,279 -58,493 -34,661 -20,378 -24,447 -21,472
Operating Margin -768.66% -645% -2,075.86% -8,011.5% -487.63% -545.04%
Earnings before Tax (EBT) 1 -55,433 -1,13,196 -47,825 -22,124 -23,901 -20,181
Net income 1 -56,236 -1,13,200 -47,825 -16,006 -24,593 -20,369
Net margin -729.2% -1,248.27% -2,864.25% -6,292.62% -490.55% -517.04%
EPS 2 -812.0 -1,600 -668.0 -189.3 -239.3 -198.2
Free Cash Flow 1 -25,788 -37,751 -23,999 -5,084 -36,328 -13,156
FCF margin -334.39% -416.29% -1,437.32% -1,998.65% -724.62% -333.94%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19/03/19 30/03/20 22/03/21 22/03/22 23/03/23 21/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,09,789 47,932 6,414 1,04,403 59,872 39,600
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -25,788 -37,751 -23,999 -5,084 -36,328 -13,156
ROE (net income / shareholders' equity) -30.6% -100% -114% -24.5% -26.3% -29.9%
ROA (Net income/ Total Assets) -17.3% -27.8% -37% -14% -12.8% -14.9%
Assets 1 3,24,937 4,07,090 1,29,334 1,14,519 1,91,762 1,36,726
Book Value Per Share 2 2,365 858.0 320.0 1,051 768.0 558.0
Cash Flow per Share 2 342.0 113.0 62.80 477.0 123.0 229.0
Capex 1 283 792 73.6 64.6 292 351
Capex / Sales 3.67% 8.73% 4.41% 25.38% 5.82% 8.92%
Announcement Date 19/03/19 30/03/20 22/03/21 22/03/22 23/03/23 21/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SILLAJEN, INC. Stock SillaJen, Inc.
-22.80% 348M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 104B
BIONTECH SE Stock BioNTech SE
-14.15% 22.41B
ARGENX SE Stock argenx SE
-1.05% 22.28B
GENMAB A/S Stock Genmab A/S
-5.29% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 17.89B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.28B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.55B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A215600 Stock
  4. Financials SillaJen, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW